#Healthcare IT Market

[zenlesszonezero]

Join Zenless Zone Zero with Tsukishiro Yanagi, the deputy leader of Hollow Special Operations Section 6! Beneath her ordinary office lady exterior lies a meticulous, emotionally intelligent big sister to the team.

[univdatosmarket]

Healthcare IT Market was valued at US$ 230 billion in 2020 and is expected to grow at a CAGR of 18% over the forecast period (2021-2027)

[evolvingdigitaltrends]

Healthcare software development has a track record of achieving security, confidentiality, and interoperability by following regulations such as HIPAA and industry standards. Read this article to intricate landscape of HIPAA-compliant Healthtech software, where every line of code carries the weight of trust and integrity.

[andy1199posts]

Healthcare IT Market - Major Revenue Surge is Predicted in the Near Future

Market Size Estimation:The total size of the healthcare IT market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of approaches was taken based on the level of assumptions used. Projected Surge in Revenue Generation:Revenue-wise, the worldwide healthcare IT market was projected to be valued at $394.6 billion in 2022…

[businesspointnews]

Healthcare IT Market Expanding at a CAGR of 10.7% During 2024-2032

IMARC Group has recently released a new research study titled “Healthcare IT Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios. How big is the healthcare IT market? The global…

[esglatestmarketnews]

Healthcare IT Industry ESG - Thematic Report

The need for sustainable strategies to conduct business responsibly and ethically has prompted healthcare IT industry players to invest in ESG practices. Robust ESG policies can foster innovation, build trust, minimize risk, reduce costs and boost trust among stakeholders. Regulators and industry leaders are assessing the demand for ESG in the healthcare sector, which can play an invaluable role in enhancing healthcare access and fostering environmental justice, diversity and workplace safety. Prominent companies have furthered their emphasis on patient access, service distribution and quality of care with a focus on social issues and sound governance. 

Stakeholders, including patients, employees, shareholders and bondholders, expect ESG to have a compelling impact on the healthcare sector. Soaring demand to minimize environmental impact and bolster product quality, labor management, access to finance and human capital development have played a pivotal role in reshaping the industry. Moreover, good corporate behavior, anti-competitive practices and transparency have remained catalysts in the landscape. 

In a bid to bring medicine and vaccines to save and improve lives, increasing access to healthcare may partly depend upon a commitment to ESG performance. The prevailing dynamics can foster sustainable value for society and business. 

Environmental Perspective

ESG action integrated into business strategy has gained ground as climate resilience garners headlines to build future healthcare organizations. Low-carbon sustainable health systems have become the talk of the town amidst the healthcare sector being infamous as a major emitter of GHG and other pollutants. For instance, Philips has been at the forefront as it has aligned its goals with UN Sustainable Development Goal 13, “Take urgent action to combat climate change and its impacts.” Overconsumption of resources, pollution, waste and soaring demand for healthcare have furthered the need for strong ESG performance.

Philips focuses on a more agile and simplified operating model, supply chain reliability, patient safety, and quality. The company is also investing in products that consume less energy and materials and contain recyclable substances. Rising adoption of digital technology, shifting consumption patterns and transition to value-based care provide opportunities for leading players to underpin solutions that enhance people’s health and protect the planet. 

Social Perspective

Employee safety risks, soaring costs of care, access to healthcare and privacy & data security have spurred the need for a robust social pillar in business operations. Reported health disparities and the prevalence of behavioral and mental health issues have compelled organizations to infuse funds into digital technology in healthcare. For instance, WELL alluded to zero reportable data breaches in 2021 in its inaugural ESG Report.

Harnessing the insights and knowledge of a diverse workforce and a strategic approach to employee development and workplace inclusion need bullish social goals. Notably, 70% of senior executive team members represented a visible minority at WELL as of June 2022. Meanwhile, Cardinal Health has fostered its diversity, equity and inclusion efforts with the representation of a 71% female and 14% ethnically diverse workforce in its executive leadership team (according to its FY 2022 ESG Report). 

Is your business one of participants in the Global Healthcare IT Industry? Contact us for focused consultation around ESG Investing, and help you build sustainable business practices.

Governance Perspective

Incumbent players have raised the bar with investments in corporate governance, board diversity, accounting, ethics and corporate behavior. An emphasis on ESG priorities can help build trust and make informed decision-making. Notably, the healthcare sector has evolving regulatory requirements, prompting prominent companies to underscore the regulatory aspect. In FY 2022, McKesson integrated regulatory excellence into its business strategy playbook as a major foundational discipline. It has also upped its investments in traceability and transparency. The company is gearing up for the next stage of the Drug Supply Chain Security Act (DSCSA), which is slated to be witnessed in November 2023. The prescription drugs are expected to be serialized in the U.S. and need to be traceable throughout the supply chain. 

ESG will continue to gain ground in the mission-driven nature of the industry as its integration into the core of the business will be pronounced in the ensuing period. Forward-looking companies have furthered their focus on organic & inorganic strategies, including but not limited to collaboration, mergers & acquisitions, technology advancements and innovations. For instance, in November 2022, the GE Board of Directors approved the spin-off of GE Healthcare. Under the ticker “GEHC,” the company was expected to start trading on Nasdaq on January 4, 2023. These trends suggest the global healthcare IT market could witness around 29.3% CAGR during the forecast period. 

About Astra – ESG Solutions By Grand View Research

Astra is the Environmental, Social, and Governance (ESG) arm of Grand View Research Inc. – a global market research publishing & management consulting firm.

Astra offers comprehensive ESG thematic assessment & scores across diverse impact & socially responsible investment topics, including both public and private companies along with intuitive dashboards. Our ESG solutions are powered by robust fundamental & alternative information. Astra specializes in consulting services that equip corporates and the investment community with the in-depth ESG research and actionable insight they need to support their bottom lines and their values. We have supported our clients across diverse ESG consulting projects & advisory services, including climate strategies & assessment, ESG benchmarking, stakeholder engagement programs, active ownership, developing ESG investment strategies, ESG data services, and building corporate sustainability reports. Astra team includes a pool of industry experts and ESG enthusiasts who possess extensive end-end ESG research and consulting experience at a global level.

For more ESG Thematic reports, please visit Astra ESG Solutions, powered by Grand View Research

[marketwire]

Healthcare IT Market size is estimated to be $205 billion in 2019 and is growing at a CAGR of 13.2% during the forecast period 2020-2025.

[wemarketresearchreport]

The global healthcare information technology (IT) market size was valued at $276 Billion in 2021, and is projected to reach $956.3 Billion by 2031, registering a CAGR of 11.96% from 2022 to 2031.

[scribefindegil]

Thinking again about how many disabled people end up getting shunted into art/craft work because like. You can technically do it. Sometimes. Yeah you make a pittance at best and are almost certainly going to make your physical health worse by pushing yourself to get things done, but what else are you gonna do? You're too sick for anyone to hire you. You're "not sick enough" to qualify for benefits. Just devote every scrap of time and energy you have to a chronically underpaid, low-prestige, incredibly labor-intensive industry. A few people manage to make it work with luck and help and the right skills. Many people don't. Everyone gets pressured to monetize their hobbies, but it's especially insidious if you're disabled because any tiny thing you manage to accomplish to bring yourself joy gets twisted into proof that you should somehow be able to work.

[sizzlingsandwichperfection-blog]

Last week, Johnson & Johnson agreed not to enforce their secondary patents on bedaquiline in most countries after a long public pressure campaign by TB activists around the world.

(A special shoutout to Nandita Venkatesan and Phumeza Tisilethe, the two women who led the charge to prevent the patent evergreening in India, which is the only reason generic bedaquiline is in production.)

But the problem of patent evergreening is everywhere--as this NYT story reports, Gilead intentionally denied people access to a drug they knew to be less toxic than alternatives because it wanted to extend its monopoly on HIV drugs for as long as possible.

Similarly, Johnson & Johnson has been intentionally denying people access to affordable bedaquiline, even though they knew they could make a profit even if they decreased the price by 65%.

What's especially galling is that both these companies benefit tremendously from public investment (bedaquiline research was funded primarily by the public), and so we end up paying for it twice--once to develop it, and once to have it available to the sick.

This is infuriating, and it is resulting in the real impoverishment and death of so many people. How does it end? With better governance and regulation. In this respect, India can be a model for us--their courts have done a much better job than U.S. ones of determining what really deserves to be patented and for how long. I'm hopeful that we can learn from the, but disgusted by this ongoing horror.

[zenlesszonezero]

Join Zenless Zone Zero with Tsukishiro Yanagi, the deputy leader of Hollow Special Operations Section 6! Beneath her ordinary office lady exterior lies a meticulous, emotionally intelligent big sister to the team.